

NEXT SCIENCE®

ASX ANNOUNCEMENT / MEDIA RELEASE
ASX: (NXS)

General Meeting – Voting Results

Sydney, Australia Wednesday, 25 October 2023, Next Science Limited (ASX: NXS) (**Next Science** or the **Company**), a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, advises that the results of the General Meeting held today are set out in the attached report.

All resolutions put to the meeting were passed by the requisite majority and determined by way of a poll.

The results are provided in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the *Corporations Act 2001* (Cth).

Further Information:

Martyn Jacobs

Head of Investor Relations

Phone: +61 412 785 180

Email: mjacobs@nextscience.com

Approved and authorised for release by the Managing Director and CEO.

Next Science Investor Hub

Next Science welcomes direct engagement and encourages shareholders and interested parties to visit the Next Science Investor Hub which provides additional background information, videos and a forum for stakeholders to communicate with each other and with the Company. Stakeholders can access the Investor Hub through the following link: <https://investorhub.nextscience.com/announcements>

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary XBIO™ technology to reduce the impact of biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its XBIO™ technology. For further information visit: www.nextscience.com

GENERAL MEETING
Wednesday, 25 October, 2023

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Direct vote (as at proxy close):		Total votes cast in the poll (where applicable)			Result
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	For	Against	Abstain **	
1	APPROVAL FOR ACQUISITION OF SHARES BY WALKER GROUP HOLDINGS PTY LIMITED	NA	12,350,796 32.93%	6,361 0.02%	388,310 1.04%	77,490	24,678,296 65.79%	85,589 0.23%	37,616,345 98.59%	537,534 1.41%	77,490	Carried
2	APPROVAL OF PRIOR ISSUE OF SHARES	NA	4,870,567 7.92%	0 0.00%	324,065 0.53%	7,480,703	56,174,512 91.38%	104,946 0.17%	61,385,245 99.17%	515,142 0.83%	7,480,703	Carried
3	APPROVAL TO ISSUE DIRECTOR PLACEMENT SHARES TO DIRECTOR, AILEEN STOCKBURGER	NA	12,332,918 13.19%	25,043 0.03%	387,980 0.41%	41,816	80,564,372 86.15%	209,814 0.22%	93,484,213 99.28%	680,441 0.72%	41,816	Carried
4	APPROVAL TO ISSUE DIRECTOR PLACEMENT SHARES TO DIRECTOR, HARRY THOMAS HALL, IV	NA	12,332,918 13.18%	25,043 0.03%	387,980 0.41%	41,816	80,609,209 86.15%	209,814 0.22%	93,529,050 99.28%	680,441 0.72%	41,816	Carried
5	APPROVAL TO ISSUE DIRECTOR PLACEMENT SHARES TO DIRECTOR, GRANT HUMMEL	NA	12,332,918 13.18%	25,043 0.03%	387,980 0.41%	41,816	80,609,209 86.15%	209,814 0.22%	93,529,050 99.28%	680,441 0.72%	41,816	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item